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ABSTRACT 
Hormonal homeostasis is essential for a variety of physiological and pathological processes. 
Elimination and detoxification of xenobiotics, such as drugs introduced into the human body, 
could disrupt the balance of hormones due to the induction of drug metabolizing enzymes 
(DMEs) and transporters. Pregnane X receptor (PXR, NR1I2) functions as a master xenobi-
otic receptor involved in drug metabolism and drug-drug interactions by its coordinated tran-
scriptional regulation of phase I and phase II DMEs and transporters. Recently, increasing ev-
idences indicate that PXR can also mediate the endocrine disruptor function and thus impact 
the integrity of the endocrine system. This review focuses primarily on the recent advances in 
our understanding of the function of PXR in glucocorticoid, mineralocorticoid, androgen and 
estrogen homeostasis. The elucidation of PXR-mediated drug-hormone interactions might 
have important therapeutic implications in dealing with hormone-dependent diseases and 
safety assessment of drugs. 
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INTRODUCTION 
Hormones, especially steroid hormones, 
act as chemical messengers to regulate a va-
riety of physiological processes (Norman et 
al., 2004), such as metabolism, development 
and growth. Disruption of hormone balance 
contributes to the pathogenesis of sexual 
dysfunction, cardiovascular diseases, meta-
bolic syndrome, and a multitude of cancers. 
It has been recognized that variations in the 
expression and/or activity levels of drug me-
tabolizing enzymes and transporters can af-
fect the biotransformation, excretion and 
function of hormones, therefore influence the 
susceptibility of individuals to certain hor-
mone-dependent diseases (Lakhani et al., 
2003; Secky et al., 2013). In this regard, 
drug-hormone interactions should be consid-
ered for safety assessment of drugs. 
There is now compelling evidence that 
several orphan nuclear receptors can function 
as “steroid receptors” by impacting steroid 
hormone homeostasis (Falkenstein et al., 
2000). Orphan nuclear receptors belong to 
nuclear receptor (NR) superfamily, whose 
endogenous and/or exogenous ligands have 
not yet been identified at the time the recep-
tors were discovered (Chawla et al., 2001; 
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Mangelsdorf and Evans, 1995). Recently, 
endogenous and/or synthetic ligands for 
many of the orphan receptors have been dis-
covered. These receptors were subsequently 
re-classified as “adopted” orphan NRs (Chai 
et al., 2013; Mukherjee and Mani, 2010). 
Examples of the “adopted” orphan NRs in-
clude pregnane X receptor (PXR; NR1I2), 
constitutive androstane receptor (CAR; 
NR1I3), liver X receptors α and β (LXRs; 
NR1H3 and NR1H2), retinoid X receptors 
(RXRs; NR2B1, NR2B2 and NR2B3), pe-
roxisome proliferator-activated receptors 
(PPARs; NR1C1, NR1C2 and NR1C3), far-
nesoid X receptor (FXR; NR1H4) and 
hepatocyte nuclear factor-4 α (HNF4α; 
NR2A1, NR2A2 and NR3A3).  
Some NRs, such as CAR, LXR, PXR and 
GR, have been reported to affect the hor-
mone regulation (Gong et al., 2007, 2008; 
Qatanani et al., 2005), among which PXR 
has been increasingly recognized for its 
function in mediating the endocrine disrupt-
ing effect and affecting steroid homeostasis. 
This is because PXR is a master xenosen-
sor involved in drug metabolism and drug-
drug interactions by its coordinated tran-
scriptional regulation of phase I/II drug me-
tabolizing enzymes (DMEs) and transporters 
(Chai et al., 2013; Chen et al., 2012; De 
Mattia et al., 2013). The same enzyme and 
transporter systems are also responsible for 
the metabolism of many of the steroid hor-
mones. Therefore, drugs that activate PXR 
can potentially impact hormonal homeosta-
sis, leading to the so-called drug-hormone 
interactions. In this review, we aim to sum-
marize the most recent findings and further 
understand the potential mechanisms by 
which PXR mediates drug-hormone interac-
tions. 
 
PXR AS A XENOBIOTIC RECEPTOR 
PXR was originally identified as a xeno-
biotic nuclear receptor highly expressed in 
the liver and intestine. PXR is involved in 
drug metabolism, bile acid transport, cancer, 
cholesterol metabolism and inflammation 
(Biswas et al., 2009; Kliewer et al., 1998; 
Lehmann et al., 1998). PXR has similar 
structure with other NRs, but a larger and 
flexible ligand-binding pocket, which ena-
bles it to accommodate a more diverse array 
of ligands (Watkins et al., 2001), including 
prescription drugs, herbal medicines, dietary 
supplements, environmental pollutants, and 
endobiotics (Ma et al., 2008; Poso and 
Honkakoski, 2006). When ligand bind to lig-
and binding domain (LBD) of PXR, it trans-
locates from the cytoplasm to the nucleus 
(Squires et al., 2004) and then binds to DNA 
binding domain (DBD) in xenobiotic re-
sponse element (XRE) as a heterodimer or 
heterotetramer with the retinoid X receptor 
(RXR) (Teotico et al., 2008). PXR can re-
cruit multiple co-activators, such as the ster-
oid receptor co-activators 1 (SRC-1), TIF/ 
GRIP (SRC-2) and PPARγ co-activator 1α 
(PGC-1α) (Li and Chiang, 2005; Mangels-
dorf and Evans, 1995; McKenna et al., 
1999), and also with nuclear receptor HNF4α 
(Guengerich, 2003; Tirona et al., 2003), 
leading to PXR-mediated transcriptional ac-
tivation of target genes. 
Among PXR domains, the LBD amino 
acid sequence of PXR are more diverse 
among species (Maglich et al., 2001), which 
is responsible for the species-specific PXR 
activation and target gene induction. For in-
stance, the antibiotic rifampicin (RIF) and 
SR12813 are effective PXR agonists for 
hPXR, but they have little effect on the 
mouse or rat PXR (Jones et al., 2000; 
Lehmann et al., 1998). Another case is that, 
the synthetic antiglucocorticoid pregne-
nolone-16a-carbonitrile (PCN) can potently 
activate the rodent PXR but has little effect 
on hPXR (Kliewer et al., 2002; Lehmann et 
al., 1998). Therefore, PXR humanized trans-
genic mice were developed and emerged as 
an important model to overcome the species 
specificity when testing compound effica-
cy in vivo and exhibited a humanized hepatic 
xenobiotic response profile (Ma et al., 2007; 
Xie et al., 2000). 
 
Drug-metabolizing enzymes and drug 
transporters regulated by PXR 
PXR is a well-established xenobiotic 
sensor that regulates various phase I/II 
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DMEs and transporters. Phase-I oxidative 
metabolism is primarily catalyzed by several 
members of the cytochrome P450 (CYP) 
family of haem-containing monooxygenase 
(Nelson et al., 1996), which are abundance in 
the liver and intestine. They play pivotal 
roles in the first stage of xenobiotic (e.g. 
drugs, environmental chemicals) and endog-
enous (e.g. lipophilic substrates, fatty acid) 
metabolism. Among these CYPs, members 
of the CYP3A family are predominantly re-
sponsible for more than 60 % metabolic sub-
strates (Rendic, 2002). The CYP3A induc-
tion by xenobiotics is now thought to be 
largely due to xenobiotic binding and tran-
scriptional activation of PXR. For example, 
PXR/RXR heterodimers bind DR3 element 
in the human CYP3A4 gene enhancer and an 
ER6 element located in the proximal pro-
moter of the CYP3A4 gene (Bertilsson et al., 
1998; Goodwin et al., 1999; Lehmann et al., 
1998) . 
Phase II enzyme genes up-regulated by 
PXR ligands include glutathione S-trans-
ferase (GST), UDP glucuronosyltransferase 
(UDPGT) ， Sulfotransferase (SULT) and 
carboxylesterase families (Falkner et al., 
2001; Hosokawa et al., 1993; Madhu and 
Klaassen, 1991). Besides the function in 
drug metabolism, SULTs have been widely 
studied due to their important role in steroid 
homeostasis and neurotransmitters (Hell-
riegel et al., 1996; Hempel et al., 2004). 
Therefore, it is not surprising that the inves-
tigation of the effects of NR (including 
PXR)-mediated regulation of SULTs on 
physiological and pathophysiological pro-
cesses is becoming active (Gamage et al., 
2006; Runge-Morris, 1998; Runge-Morris et 
al., 2013). 
Finally the removal of toxicant from 
body is accomplished by phase III transport-
ers, among the hepatic transporters, PXR has 
been shown to stimulate the expression of 
Oatp1a4, Oatp21 (Oatp1b1), MDR1, MRP2 
and MRP3 differently in rodents and human 
(Chai et al., 2013).  
Taken together, PXR coordinately regu-
lates multistep system consisting of three 
groups of proteins in the liver and intestine 
that are involved in all aspects of the detoxi-
fication and elimination of xenobiotics from 
the body (Xu et al., 2005). 
 
PXR in drug metabolism and drug-drug 
interactions  
Our body is confronted daily with a wide 
array of environmental chemicals, including 
prescription drugs, over-the-counter medica-
tions and herbal medicines, which may exert 
toxic effects through various mechanisms, 
especially when there’s excess accumulation 
(Zhang et al., 2008). PXR mediated induc-
tion of DMEs and transporters can recognize 
a large spectrum of pharmaceutical sub-
strates, relevant gene-inducing drugs and 
thus potentially be capable of affecting the 
metabolism and clearance of co-consumed 
drugs. 
Recent studies have suggested that in an-
ticancer chemotherapy where drug combina-
tion therapies are typically employed, activa-
tion of PXR may compromise the effective-
ness of antineoplastic drugs and contribute to 
drug resistance (Chen, 2010). For example, 
paclitaxel is one of the most commonly used 
antineoplastic agents in human breast cancer 
(Chen et al., 2009; Choi et al., 2007), ovarian 
cancer (Gupta et al., 2008) and prostate can-
cer cell lines (Chen et al., 2007). Several in 
vitro studies demonstrated that the activity of 
paclitaxel is significantly reduced by 
paclitaxel induced activation of PXR and 
hence the induction of metabolic drug inacti-
vation (i.e., CYP3A4) and drug efflux trans-
porters (i.e., MDR1). Additionally, a study 
of breast cancer patients treated with tamoxi-
fen-based adjuvant therapy demonstrated an 
association between higher PXR expression 
in tumor tissue and resistance to tamoxifen, 
which resulted in a higher probability of re-
lapse (Conde et al., 2008). The identification 
of rifampicin as a potent hPXR agonist has 
also provided an explanation as to why this 
drug is an efficient inducer of drug-
metabolizing enzymes compromising the 
effectiveness of other drugs. Other than ri-
fampicin and paclitaxel, Sinz and colleagues 
summarized a more comprehensive analysis 
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of the effect of commonly used clinical 
drugs on PXR activation(Sinz et al., 2006). 
The regulation of drug-metabolizing en-
zymes by PXR is also implicated in clinical 
drug–drug interactions, in which one drug 
accelerates the metabolism of a second co-
administered medication and consequently 
affecting the efficiency of other drugs or 
cause possible adverse results. It was report-
ed that a significant high incidence of un-
wanted pregnancies occurred in female pa-
tients using oral contraceptives and an-
tituberculosis drug rifampicin simultaneous-
ly in the early 1970s for rifampicin activated 
PXR accelerated the metabolism of contra-
ceptives (Reimers and Jezek, 1971). As ex-
pected, co-administration of the CYP3A4 
inducing St. John’s Wort (SJW), a popular 
herbal antidepressant, together with cyclo-
sporine leads to enhanced metabolism and 
clearance of cyclosporine due to the similar 
pharmacokinetic interactions (Gibson et al., 
2002). In an investigation of several tradi-
tional Chinese medicines (TCMs), two TCM 
herbs, Wu Wei Zi and Gan Cao were shown 
to be capable of activating PXR and admin-
istration of both two herbs in rats increased 
the metabolism of coadministered warfarin 
(Mu et al., 2006), reinforcing concerns in-
volving the safe use of herbal medicines to 
avoid PXR-mediated drug-drug interactions.  
Moreover, accelerated metabolism might 
be harmful for some drugs because of the 
production and accumulation of toxic me-
tabolites. For example, co-administration of 
rifampicin with acetaminophen can increase 
toxic responses to drugs via up-regulation of 
CYP3A4 (Crippin, 1993). Likewise, SJW 
(another PXR agonists)  has been reported to 
trigger severe adverse interactions with a 
number of clinical drugs, such as anticancer 
agents (imatinib and irinotecan), anti-HIV 
agents (e.g. indinavir, lamivudine and nevi-
rapine), anti-inflammatory agents (e.g. ibu-
profen and fexofenadine) (Di et al., 2008). 
Taken together, cautions should be taken 
when these PXR activators are used in com-
bination with prescribed drugs. 
The identification and development of 
PXR antagonists have their implications in 
drug metabolism and may be useful to pre-
vent harmful drug–drug interactions and thus 
improve the therapeutic efficacy of therapeu-
tics. There is a growing list of large- and 
small-molecule PXR antagonists that in-
cludes anticancer compound ET-743 (Synold 
et al., 2001), Rand A-792611 (Healan-
Greenberg et al., 2008), polychlorinated bi-
phenyls (Tabb et al., 2004) and ketoconazole 
(Huang et al., 2007), fluconazole and eni-
conazole (Wang et al., 2007), sulforaphane 
(Zhou et al., 2007) and coumestrol (Wang et 
al., 2008). PXR antagonist pharmacophore 
models were developed using computational 
approaches based on the three azoleantago-
nists and biphenyls (Ekins et al., 2008). By 
using this approach, Ekins et al. discovered 
several new PXR antagonists with in vitro 
activity and their data suggested that most of 
the known PXR antagonists interact on the 
outer surface of PXR at the AF-2 domain 
and disrupt the recruitment of co-activators 
(Ekins et al., 2008). More recently, Li et al. 
(2013) developed a novel yeast-based two-
hybrid assay and molecular docking analysis 
to define an antagonist, ketoconazole’s, 
unique binding residues such as Ser-208, 
which is on the opposite side of the protein 
from the AF-2 region critical for receptor 
regulation. Further investigation is needed to 
develop potent, tissue-selective PXR antago-
nists that may be useful in clinical applica-
tion. For example, selectively target neo-
plastic cells or disrupt undesirable PXR-
mediated up-regulation of drug metabolism 
in the liver or elsewhere (Biswas et al., 
2009). This can be achieved by modification 
and optimization of the functional groups of 
our recently discovered antagonists, thus 
generate new analogs with improved potency 
and selectivity against hPXR.  
However, it should be pointed out that 
some drug–drug interactions may be benefi-
cial by reducing the adverse reactions of an 
anti-cancer agent. Recently, a randomized 
clinical trial has demonstrated that Chinese 
herbal medicine reduces chemotherapy-
inducedside effects in vivo (Lam et al., 2010; 
Lee et al., 1999; Mehendale et al., 2004). 
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Although PXR is a master regulator of 
xenobiotic metabolism, evolving evidence 
has pointed to an equally important role of 
PXR as an ‘endobiotic receptor’ that re-
sponds to a wide array of endogenous chem-
icals (endobiotics). Moreover, the activation 
of PXR by endogenous or xenobiotic ligands 
demonstrated that PXR has been implicated 
in a number of physiological and pathophy-
siological processes. For example, PXR sig-
naling contributes to bile acid (Staudinger et 
al., 2001; Xie et al., 2001), lipid (Zhou et al., 
2006a), bone (Tabb et al., 2003; Xu et al., 
2006), inflammatory responses (Păunescu, 
1970; Gu et al., 2006; Zhou et al., 2006b) 
and glucose homeostasis and energy metabo-
lism (Gao and Xie, 2010; Spruiell et al., 
2014). 
Steroid hormones are important endobi-
otics, the formation and elimination of which 
involve many drug-metabolizing enzymes 
and transporters. As expected, emerging evi-
dence has indicated that PXR might have 
broad implications in steroid hormone ho-
meostasis and drug-hormone interactions.  
 
PXR IN GLUCOCORTICOID  
AND MINERALOCORTICOID  
HOMEOSTASIS 
Glucocorticoids (cortisol in human, cor-
ticosterone in rodents) and mineralocorti-
coids (aldosterone, deoxycorticosterone) are 
essential endocrine hormones, whose home-
ostasis is essential for the appropriate func-
tion of many cell types and for various phy-
siological processes. 
Altered glucocorticoid levels due to 
stress or upon medication (dexamethasone, 
synthetic glucocorticoid) can activate PXR 
and thus may significantly influence the de-
toxification of many endogenous and exoge-
nous chemicals (Kliewer et al., 1998; 
Pascussi et al., 2000).Another study indicates 
that CYP3A4 induction by phthalates is de-
pendent on glucocorticoid induced PXR ex-
pression (Cooper et al., 2008). 
On the other hand, PXR can also regulate 
glucocorticoid and mineralocorticoid homeo-
stasis. The PXR target gene, CYP3A4 exhib-
its a significant role in cortisol metabolism 
(Buters et al., 1994). And cortisol activities 
were also used as biomarkers for CYP3A4 
induction or inhibition (Fayer et al., 2001; 
Konishi et al., 2004). 
Our study showed that genetic (VP-
hPXR transgene) and pharmacological (lig-
and, RIF) activation of hPXR in mice mark-
edly increased plasma concentrations of cor-
ticosterone and aldosterone, glucocorticoid 
and mineralocorticoid respectively (Zhai et 
al., 2007). The increased levels of corti-
costerone and aldosterone were associated 
with elevated expression of adrenal steroido-
genic enzymes, including Cyp11a1, 
Cyp11b1, Cyp11b2 and 3β-hydroxysteroid 
dehydrogenase. The PXR-activating trans-
genic mice also exhibited hypertrophy of the 
adrenal cortex, loss of glucocorticoid circa-
dian rhythm as well as impaired stress re-
sponses. However the function of HPA axis 
of the VP-hPXR transgenic mice was intact 
despite a severe disruption of adrenal steroid 
homeostasis (Zhai et al., 2007).  
Hypercortisolism is the clinical hallmark 
of the pseudo-Cushing's syndrome in pa-
tients. This syndrome is most seen in people 
who are alcohol abuse, depressed or obese. 
However, Zhang suggested that these sus-
ceptible patients might be associated with 
increased expression and/or activity of PXR 
(Zhang et al., 2008). As a proof, PXR-
activating transgenic mice and rifampicin 
treated tuberculosis patients can also show 
hypercortisolism (Zawawi et al., 1996). The 
glucocorticoid elevation effect appeared to 
be PXR-specific, as the activation of CAR in 
transgenic mice had little effect on the ho-
meostasis of the glucocorticoids. We propose 
that PXR is a potential endocrine disrupting 
factor that may have broad implications in 
steroid homeostasis and drug-hormone inter-
actions (Zhai et al., 2007). 
 
PXR IN ANDROGEN HOMEOSTASIS 
Chen et al. first detected the differential 
expression of PXR in normal and cancerous 
prostate tissues (Chen et al., 2007). In PC3 
human prostate carcinoma cells, activation of 
PXR with SR12813 enhanced the expression 
of both CYP3A4 and MDR1 that accelerate 
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the metabolism and the elimination of anti-
cancer drugs, contributing to the resistance 
of PC3 cells to these drugs, such as paclitax-
el and vinblastine. On the other hand, the 
targeted knockdown of PXR using shRNA 
decreased the activity of PXR towards the 
promoter of CYP3A4 and increased the sen-
sitivity of PC3 cells to paclitaxel and vin-
blastine, suggesting that down-regulation of 
PXR sensitizes prostate cancer cells toward 
chemotherapy. The results indicated that 
PXR may be important in prostate cancer 
resistance to chemotherapeutic agents. Addi-
tionally, another study suggested that PXR 
may be a strong prognostic indicator of fa-
vorable outcomes, for clinical results indi-
cated that higher PXR expression was corre-
lated with increased survival rate of prostate 
cancer patients (Fujimura et al., 2012). 
Recently, a novel PXR-mediated and me-
tabolism-based mechanism to reduce andro-
gen activity was reported. CYP3As and 
SULT2A1 are enzymes important for the 
metabolic deactivation of androgens. 
CYP3A is the key enzyme in catalyzing hy-
droxylation of testosterone and progesterone, 
leading to inactivation of hormones (Buters 
et al., 1994; Niwa et al., 1998). SULT2A1 is 
the primary SULT isoform responsible for 
the sulfonation and deactivation of androgen 
(Strott, 2002). The study showed that genetic 
or pharmacological activation of PXR re-
duced the androgenic activity and inhibited 
androgen-responsive prostate regeneration in 
castrated male mice receiving daily injec-
tions of testosterone propionate by inducing 
the expression of CYP3As and hydroxyster-
oid SULT2A1. 
Importantly, in human prostate cancer 
cells, treatment with the PXR agonist rifam-
picin inhibited androgen-dependent prolifer-
ation of LAPC-4 cells, but had little effect on 
the growth of the androgen-independent iso-
genic LA99 cells. Down-regulation of PXR 
or SULT2A1 in LAPC-4 cells by shRNA or 
siRNA abolished the rifampicin effect, indi-
cating that the inhibitory effect of rifampici-
non androgens was PXR- and SULT2A1-
dependent. Based on these data, PXR and its 
target androgen metabolizing enzymes may 
represent novel therapeutic target for hor-
mone-dependent prostate cancer (Zhang et 
al., 2010). 
 
A POTENTIAL ROLE OF PXR IN  
ESTROGEN HOMEOSTASIS 
Estrogens play an important role in vari-
ous of physiological or pathophysiological 
processes, which are including development 
(Nilsson and Gustafsson, 2002), cardiovas-
cular diseases and metabolic disorders such 
as obesity and type 2 diabetes (Mauvais-
Jarvis et al., 2013). Most, if not all, hormone 
replacement therapy regimens containing 
estrogens either alone or in combination with 
progestins have been widely used to treat 
menopause related syndromes (Warren, 
2004). In addition, endocrine-based therapies 
against ER+ breast cancers including antag-
onize ER function with synthetic selective 
estrogen receptor modulators (SERMs) (e.g. 
tamoxifen) or down-regulate estrogen activi-
ties (antiestrogens and aromatase inhibitors) 
(Patel et al., 2007), have been proven effec-
tive to treat breast cancers. However, subse-
quently side effects such as resistance to 
aromatase inhibition and risk for endometrial 
cancer are frequent during these treatments. 
So it is rewarding to develop novel and ef-
fective estrogen deprivation strategies. 
Among the major PXR induced human 
hepatic P450s, CYP3A4, which can be acti-
vated by PXR as we previously mentioned, 
most efficiently catalyzes 6β- and 16α-
hydroxylation of progesterone (Niwa et al., 
1998). It also catalyzes 2-,4-, and 16-hydro-
xylation of estradiol, leading to estrogen de-
activation (Badawi et al., 2001; Lee et al., 
2001). In a CYP3A4-transgenic mouse line, 
females were found to be deficient in lacta-
tion, leading to a markedly lower pup sur-
vival. This impaired lactation phenotype was 
associated with significantly reduced serum 
estradiol levels in CYP3A4, suggesting that 
CYP3A4 may play an important role in es-
trogen homeostasis (Yu et al., 2005). This 
may be of relevance in administrating drugs 
that are PXR activators to pregnant and lac-
tating women. Notably, rifampicin，a PXR 
agonist, is contraindicated in pregnancy ex-
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cept in the presence of a severe disease un-
treatable with other drugs, such as tuberculo-
sis. Teratogenicity was found in animals ad-
ministered with rifampicin and also there 
were case reports of malformation, death and 
hemorrhagic disorders in infants whose 
mothers were undergoing rifampicin therapy 
due to estrogen homeostasis disorder caused 
by rifampicin triggered PXR activation (Ma 
and Lu, 2008).  
Another critical metabolic pathway to 
deactivate estrogens is through the estrogen 
sulfotransferase (EST, or SULT1E1)-
mediated sulfation, because sulfonated es-
trogens cannot bind to and activate ER, thus 
losing their estrogenic activities (Song, 
2001). In 2012, a study conducted by Gao et 
al. showed that loss of SULT1E1 in female 
mice improved metabolic function in ob/ob, 
dexamethasone- and high-fat diet-induced 
mouse models of type 2 diabetes, which 
might result from decreased estrogen depri-
vation and increased estrogenic activity in 
the liver (Gao et al., 2012). 
Recently Kodama et al. (2011) revealed a 
novel function of PXR in estrogen homeo-
stasis related to SULT1E1. The study found 
that, upon activation by rifampicin, PXR, via 
its interactions with HNF4α, prevents the 
promoter from forming the active chromatin 
structure, thereby repressing the transcription 
of SULT1E1 in human primary hepatocytes 
and hepatocellular carcinoma Huh7 cells. 
Therefore hPXR activation would tip the 
hepatocellular androgen/estrogen balance 
toward greater estrogenicity by attenuating 
the inactivation of estrogen (Kodama et al., 
2011), thereby affecting the physiology 
and/or pathophysiology of liver. 
 
SUMMARY AND PERSPECTIVE 
Based on this review, it will be clear that 
novel molecular targets of PXR-mediated 
hormone regulation may have implications 
in the prevention and treatment of hormone-
related endocrine disorders and other meta-
bolic diseases (Figure 1), such as diabetes 
and obesity. What’s more, PXR activities are 
not limited to regulating glucocorticoid, 
mineralocorticoid, androgen, and estrogen 
homeostasis. For example, PXR agonist 
DMP 904 (Wong et al., 2005) was demon-
strated to have effects on thyroid hormone 
homeostasis in rats. 
 
 
 
 
Figure 1: Schematic representation of the role of PXR in hormone metabolism
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However using PXR manipulation as a 
strategy to alter hormone activity generates 
many challenges and sparks concerns regard-
ing the PXR-induced harmful drug-drug in-
teractions. On one hand, PXR is promiscu-
ous and unique in that it is activated by a di-
verse group of xenobiotics, including thera-
peutic anticancer drugs and naturally-
occurring endocrine disruptors. On the other 
hand, drugs mediated PXR activation in-
clined to interfere with endocrine hormone 
system and alter the metabolic changes. 
Therefore, the PXR-mediated drug-drug and 
drug-hormone interactions further prompt 
the development of antagonists of PXR to 
avoid undesirable PXR activation in patients 
undergoing combination or hormone thera-
pies. We face the challenge of making ap-
propriate drug management by balancing the 
beneficial effects against potential risks of 
drugs. 
Taken together, the role of PXR in drug-
hormone interactions may provide an im-
portant clue as to the mechanism by which 
PXR agonist/antagonists disrupting the en-
docrine system of body. However, this re-
view of evidences regarding PXR mediated 
drug-hormone interactions is still far from 
comprehension. A more complete under-
standing of mechanism underlying PXR as a 
potential endocrine disruptor is necessary to 
interrogate the physiological and/or patho-
physiological roles of PXR. 
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